DK2329848T3 - Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes - Google Patents

Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes

Info

Publication number: DK2329848T3
Authority: DK; Denmark
Prior art keywords: lixisenatide; metformin; diabetes; treatment; type
Prior art date: 2009-11-13

Application number

DK09175877.1T

Other languages

English (en)

Other versions

DK2329848T4 (da

Inventor

Louise Silvestre

Elisabeth Souhami

Xiaodan Wei

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-13

Filing date

2009-11-13

Publication date

2013-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41800749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2329848(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-13 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2013-02-04 Application granted granted Critical

2013-02-04 Publication of DK2329848T3 publication Critical patent/DK2329848T3/da

2019-09-09 Publication of DK2329848T4 publication Critical patent/DK2329848T4/da

Links

108010057186 Insulin Glargine Proteins 0.000 title 1
COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 title 1
XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
238000011360 adjunctive therapy Methods 0.000 title 1
229960002869 insulin glargine Drugs 0.000 title 1
229960001093 lixisenatide Drugs 0.000 title 1
108010004367 lixisenatide Proteins 0.000 title 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
229960003105 metformin Drugs 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK09175877.1T 2009-11-13 2009-11-13 Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes DK2329848T4 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09175877.1A EP2329848B2 (en)	2009-11-13	2009-11-13	Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes

Publications (2)

Publication Number	Publication Date
DK2329848T3 true DK2329848T3 (da)	2013-02-04
DK2329848T4 DK2329848T4 (da)	2019-09-09

Family

ID=41800749

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09175877.1T DK2329848T4 (da)	2009-11-13	2009-11-13	Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes

Country Status (11)

Country	Link
EP (1)	EP2329848B2 (da)
CY (1)	CY1113755T1 (da)
DK (1)	DK2329848T4 (da)
ES (1)	ES2398012T5 (da)
HR (1)	HRP20121029T4 (da)
ME (1)	ME01546B (da)
PL (1)	PL2329848T5 (da)
PT (1)	PT2329848E (da)
RS (1)	RS52629B2 (da)
SI (1)	SI2329848T2 (da)
SM (1)	SMT201300013B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3228320B1 (de)	2008-10-17	2019-12-18	Sanofi-Aventis Deutschland GmbH	Kombination von einem insulin und einem glp-1-agonisten
BR112012011403B8 (pt)	2009-11-13	2021-05-25	Sanofi Aventis Deutschland	composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
CA2780460C (en)	2009-11-13	2018-09-04	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
EP2611458B1 (en)	2010-08-30	2016-09-21	Sanofi-Aventis Deutschland GmbH	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CA2825162A1 (en) *	2011-02-02	2012-08-09	Sanofi-Aventis Deutschland Gmbh	Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2550357T3 (es)	2011-08-29	2015-11-06	Sanofi-Aventis Deutschland Gmbh	Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
KR101967941B1 (ko) *	2011-10-28	2019-04-10	사노피-아벤티스 도이칠란트 게엠베하	제2형 당뇨병 치료 프로토콜
RU2705797C2 (ru)	2013-04-03	2019-11-12	Санофи	Лечение сахарного диабета с помощью составов инсулинов длительного действия
HRP20190557T1 (hr) *	2013-06-17	2019-05-03	Sanofi-Aventis Deutschland Gmbh	Formulacija s fiksnim omjerom inzulin glargin/liksisenatid
MX389178B (es)	2014-12-12	2025-03-20	Sanofi Aventis Deutschland	Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels

2009
- 2009-11-13 PL PL09175877T patent/PL2329848T5/pl unknown
- 2009-11-13 ME MEP-2012-147A patent/ME01546B/me unknown
- 2009-11-13 DK DK09175877.1T patent/DK2329848T4/da active
- 2009-11-13 EP EP09175877.1A patent/EP2329848B2/en active Active
- 2009-11-13 ES ES09175877T patent/ES2398012T5/es active Active
- 2009-11-13 RS RS20120571 patent/RS52629B2/sr unknown
- 2009-11-13 PT PT91758771T patent/PT2329848E/pt unknown
- 2009-11-13 SI SI200930473T patent/SI2329848T2/sl unknown
2012
- 2012-12-13 HR HRP20121029TT patent/HRP20121029T4/hr unknown
2013
- 2013-01-09 CY CY20131100022T patent/CY1113755T1/el unknown
- 2013-01-30 SM SM201300013T patent/SMT201300013B/xx unknown

Also Published As

Publication number	Publication date
HRP20121029T1 (hr)	2013-01-31
PL2329848T3 (pl)	2013-05-31
EP2329848A1 (en)	2011-06-08
PL2329848T5 (pl)	2019-12-31
ES2398012T3 (es)	2013-03-13
EP2329848B1 (en)	2012-10-24
CY1113755T1 (el)	2016-07-27
DK2329848T4 (da)	2019-09-09
RS52629B (en)	2013-06-28
SI2329848T1 (sl)	2013-02-28
SI2329848T2 (sl)	2019-10-30
SMT201300013B (it)	2013-03-08
ME01546B (me)	2014-04-20
HRP20121029T4 (hr)	2019-10-18
EP2329848B2 (en)	2019-06-19
PT2329848E (pt)	2013-01-23
RS52629B2 (sr)	2019-11-29
ES2398012T5 (es)	2020-02-26

Similar Documents

Publication	Publication Date	Title
DK2329848T4 (da)	2019-09-09	Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes
DK2419097T3 (da)	2013-10-28	Farmaceutisk sammensætning omfattende (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol og metformin og anvendelser deraf i behandling af diabetes
NO2017030I1 (no)	2017-07-04	insulin glargine/lixisenatide
PL2707017T3 (pl)	2016-03-31	Liksisenatyd i metformina do leczenia cukrzycy typu 2
PL2324853T3 (pl)	2016-01-29	Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
DK3524261T3 (da)	2024-01-15	Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
DK2611458T3 (da)	2017-01-02	Anvendelse af ave0010 til fremstilling af et medikament til behandling af diabetes mellitus type 2
ATE522545T1 (de)	2011-09-15	Amidiertes insulin glargin
IL209887A0 (en)	2011-02-28	Treatment for diabetes in patients inappropriate for metformin therapy
BRPI0915838A2 (pt)	2015-11-03	compostos de insulina lispro peguilados
DK2451482T3 (da)	2019-07-22	Kombinationsterapi til behandlingen af diabetes
BRPI0818872A2 (pt)	2015-05-05	Método para prevenir efeitos adversos por glp-1
EA201391028A1 (ru)	2013-12-30	Гиполипидемическое противодиабетическое средство
DK3338791T3 (da)	2019-12-16	Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt
DK2114386T3 (da)	2013-03-18	Farmaceutisk sammensætning til behandling af diabeteskomplikationer
BR112013029256A2 (pt)	2016-11-29	"combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
BRPI0906094A2 (pt)	2016-07-05	composto e método de tratamento de diabetes do tipo ii
DK2864473T3 (da)	2019-09-23	Stamceller og pankreatiske celler som kan anvendes til behandlingen af insulin-afhængig diabetes mellitus
DK2268624T3 (da)	2013-11-04	Arylpyrazinon-derivater som insulin-sekretions-stimulatorer, fremgangsmåde til opnåelse deraf og anvendelse deraf til behandlingen af diabetes
DE602007005257D1 (de)	2010-04-22	Armbanduhrgehäuse
EP2575826A4 (en)	2013-11-13	ANTIDIABETIC COMPOSITIONS AND ASSOCIATED METHODS
GB0919603D0 (en)	2009-12-23	Use of thymosin beta-4 for treatment of type II diabetes
EP2331099A4 (en)	2012-02-29	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS
TH0901003547A (th)	2016-02-15	การรักษาสำหรับโรคเบาหวานในคนไข้ที่ไม่เหมาะสำหรับการรักษาด้วยเมทฟอร์มิน
TH93149B (th)	2009-01-30	นาฬิกาข้อมือ